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Abstract
Background: The basic defect of the autosomal recessive disorder cystic ﬁbrosis (CF) manifests in chloride hyposecretion and sodium hyper-
absorption. CF-like disease has been reported in a heterozygous carrier of F508del CFTR and the hyperactive variant p.W493R-SCNN1A of the
epithelial sodium channel (ENaC).
Methods: The hypothesis that heterozygosity for p.W493R-SCNN1A and one loss-of-function CFTR mutation causes or predisposes to CF or
CF-like disease was tested in 441 parents of a child with CF.
Results: p.W493R-SCNN1A was detected in three female carriers of F508del CFTR who did not show any symptoms of respiratory or intestinal
disease that could be interpreted as the manifestation of CF or CFTR-related disorder. Frequency of p.W493R was lower in CF parents than in
Caucasian control subjects.
Conclusions: A hyperactive ENaC does not necessarily cause CF-like disease in a CF gene carrier, but its low frequency in CF parents suggests
that it is a risk factor.
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Cystic fibrosis (CF) is an autosomal recessive disease of so-
dium and chloride ion transport that typically is caused by
loss-of-function mutations in both copies of the CFTR gene
[1]. In a minority of CF patients a mutation cannot be identified
on both CFTR genes. Since increased sodium absorption
through the amiloride sensitive epithelial sodium channel
(ENaC) is part of the basic CF pathophysiology [2], mutations
in the SCNN1ABC genes that encode the three subunits of
ENaC are prime candidates that could explain disease in patients⁎ Corresponding author at: Klinische Forschergruppe‚ Molekulare Pathologie
der Mukoviszidose‘, Klinik für Pädiatrische Pneumologie, Allergologie und
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doi:10.1016/j.jcf.2011.08.008with CF-like disease in whom a mutation was not identified in
both CFTR genes. CF disease-causing mutations in SCNN1A
[3,4] and SCNN1B [5] have indeed been detected in a few
index cases. Moreover, SCNN1 polymorphisms were found to
be more frequent in this patient group indicating that ENaC var-
iants are risk factors for the emergence of CF-like disease. In
particular, Azad and co-workers [4] identified a significantly
higher number of heterozygous carriers of the hyperactive
p.W493R-SCNN1A variant in patients with CF-like disease who
either carry no or one CF-causing mutation in their two CFTR
alleles. Intriguingly, one individual with severe lung disease
and intermediary sweat chlorides was identified who carries
both F508del-CFTR and p.W493R-SCNN1A in the heterozy-
gous state. In this individual CFTR function was probably re-
duced by about 50% and ENaC function was doubled. Azad et
al. [4] hypothesized that such a combination of p.W493R-
SCNN1A with a loss-of-function mutation in one copy of the
CFTR gene may cause or predispose to CF or CF-like disease.by Elsevier B.V. All rights reserved.
Table 1
CFTR mutations in the study population of parents with at least one CF child.
A. Caucasians a
F508del 378 2184delA 2
CFTRdele2,3(21 kb) 4 2789+5 G-A 1
R117H 1 I1005R 1
405+1 G-A 1 L1077P 1
H199Y 1 Y1092X 1
L206W 1 3601−111 G-C 1
R347P 3 3849+10 kb C-T 1
Q414X 1 3850−3 T-G 1
G551D 4 W1282X 1
R553X 8 N1303K 2
1717-1 G-A 1 4374+1 G-T 1
2143delT 1 Unknown 9
B. Turks
K68N 1 1525−1 G-A 1
G85E 1 F508del 2
E92K 1 1677delTA 1
CFTRdele2(ins186) 2 2184delA 1
CFTRdele2,3(21 kb) 2 3601−2 A-G 1
435insA 1 Unknown 1
a The subjects were born in Austria (N=9 subjects), Belgium (2), France (4),
Germany (374), Greece (4), Italy (12), The Netherlands (7), Poland (2), Spain
(5), Sweden (2) and United Kingdom (5).
Table 2
Incidence of heterozygous p.W493R-SCNN1A carriers.
Cohort No.
of
subjects
No. of W493R
carriers
(% of subjects)
Turkish CFTR mutation carriers 15 0 (0%)
Caucasian F508del CFTR carriers 378 3 (0.8%)
Caucasian non-F508del CFTR mutation carriers 48 0 (0%)
Caucasian patients with CF-like disease
with no or one CFTR mutation [4]
76 6 (7.9%)
Caucasian control population [4] 739 23 (3.1%)
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population of CF parents for the presence of the p.W493R-
SCNN1A variant, the most frequent functional polymorphism
in the ENaC coding sequence.
2. Material and methods
After informed consent had been provided, a sample of at least
5 mL K-EDTA blood was drawn from heterozygous carriers of a
CFTRmutation who had at least one child with cystic fibrosis. At
the day of sampling, the diagnosis of CF had already been estab-
lished in offspring by typical clinical features of CF disease and
sweat chloride concentrations of more than 60 mval/L on at
least three independent occasions.
A cascade approach was taken to identify the CFTR muta-
tion in genomic DNA from the nuclear blood cells [6–8].
First, frequent CFTR mutations were directly tested by estab-
lished polymerase-chain reaction (PCR)-based protocols. Next,
the 27 exons of the CFTR gene together with their flanking intron
regions were amplified separately by PCR and the generated PCR
fragments were then sequenced by direct genomic sequencing.
Specimens which were refractory to amplification by PCR were
scanned for genomic rearrangements by Southern hybridization
with PCR generated genomic probes encompassing the respec-
tive exon and flanking intron sequences. If at the day of sampling
two common disease-causing CFTR mutations had already been
identified in the affected CF child, only these two mutations were
tested in its father and/or mother.
The presence of the p.W493R variant (rs5742912) in
SCNN1A was tested by the amplification of genomic DNA by
PCR with the primers 5′-TGCAGGTTAGTGTCCCCTTC
and 5′-TTCTGTCGCGATAGCATCTG, digestion of the 358-
bp PCR product with the restriction endonuclease Hpy99I and
separation of the restricted PCR product by 2.5% agarose gel
electrophoresis. Hpy99I recognizes the infrequent R493 ‚T′allele,
but not the commonW493 ‚C′allele. An unrelated sequence with
a single Hpy99I recognition site served as the positive control of
the restriction digestion.
The study has been approved by the Ethics Committee of the
Medizinische Hochschule Hannover (study nos. 2771, 3739,
and 5391).
3. Results
We searched for CFTR mutations in first-generation CF
families. 441 obligatory CF carriers of Caucasian (n=426) or
of Turkish (n=15) descent participated in the study. Carriers
had at least one CF child elder than 10 years. Genomic DNA
samples were available from both father and mother in 169
cases and from only one parent in 103 cases. Table 1 lists the
identified CFTR mutations. A CFTR mutation was detected in
100% of the 420 PI CF alleles, but only in 52% of the 21 PS
CF alleles (Table 1). The most common mutation F508del
was present in 380 carriers (86% of study population).
Next, the panel of CF carriers was screened for the presence of
the variant p.W493R in SCNN1A encoding the alpha-subunit of
the epithelial sodium channel. The hyperactive p.W493R variantwas detected in three female F508del carriers (Table 2). Azad
et al. [4] and the 1000 Genomes Project [9,10] determined the fre-
quencies of p.W493R in the general population to be 3.1% and
1.3%, respectively. The observed number of three carriers of
this functional ENaC polymorphism in our study population is
consistent with the number of subjects predicted from the 1000
Genome Project data but not with that predicted from Azad's
data. The samples utilized for the 1000 Genomes Project are de-
rived from individuals of different world populations [9], whereas
Azad et al. collected control samples from Mideuropeans. Since
the latter collection matches with the geographic origin of our
study population, the frequency of 3.1% should be the more accu-
rate value for the incidence of W493R alleles in the Mideuropean
population.
The three F508del-CFTRW493R-SCNN1A carriers were in-
conspicuous in their phenotype. They did not show any symp-
toms of chronic respiratory or intestinal disease that could be
interpreted as the manifestation of mild CF, atypical CF [11]
or CFTR-related disorder [12].
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This study screened a population of CF parents for the pres-
ence of the p.W493R-SCNN1A variant. The observed frequency
of p.W493R of 0.7% in CF parents is significantly lower than
that of 3.1% (95% confidence interval: 1.1%–6.8%) reported
by Azad et al. for Caucasian control subjects [4]. This lower fre-
quency points to possible handicaps of W493R-SCNN1A CF
gene carriers at the preconceptional (illness, reduced fertility) or
postconceptional state to generate viable babies with CF. In
other words, heterozygosity for W493R-SCNN1A and a loss-of-
function CFTR mutation may impede personal health and/or re-
productive fitness. To validate this statement drawn from the di-
vergent allele frequencies of p.W493R-SCNN1A in CF parents
and healthy non-CF carriers, the findings of this study need to
be replicated in an independent cohort of CF parents and controls.
However, even if this statement will remain true at the epidemio-
logical level of the population, it will not be predictive for the in-
dividual case. The three CF mothers in our study population who
are harboring F508del-CFTR and W493R-SCNN1A have yet not
experienced any acute or chronic illness that is related to the clin-
ical manifestations of CF or CFTR-related disorders. Thus, if a
hyperactive ENaC contributes to disease in CF gene carriers, fur-
ther yet unknown genetic or environmental factors are additional-
ly necessary to predispose to CF-like disease. This statement is
consistent with Azad's assumption that the combined carriage
of p.W493R-SCNN1A and of a CFTR gene mutation will possi-
bly cause disease by a not fully-penetrant mechanism [4]. If pen-
etrance is low, no affected subject may be detected in a small
sample such as ours of just three index cases. In summary, this
study shows that a hyperactive ENaC does not necessarily
cause CF-like disease in a CF gene carrier, but its low frequency
in CF parents suggests that it is a risk factor of health and/or re-
productive fitness.
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